SCHEMBL640746

SCHEMBL640746

COc1cccc2oc3ccccc3c(=O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 9/20 1.00
NPC1 O15118 5/20 0.69
KDM4E B2RXH2 4/20 0.69
RAB9A P51151 4/20 0.69
ALDH1A1 P00352 3/20 0.69
LMNA P02545 1/20 0.69
ESR1 P03372 1/20 0.68
KDM5A P29375 1/20 0.68
ESR2 Q92731 1/20 0.68
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
CYP3A4 P08684 3/20 0.57
HSD17B10 Q99714 3/20 0.57
HPGD P15428 2/20 0.57
CYP2C9 P11712 1/20 0.57
TSHR P16473 1/20 0.57
CYP2C19 P33261 1/20 0.57
GLA P06280 1/20 0.57
MAPT P10636 1/20 0.57
PGAM1 P18669 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20346617 0.88 MAOA (0.78) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL20350007 0.87 MAOA (0.77) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL21874395 0.86 MAOA (0.75) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL5026754 0.85 MAOA (0.74) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL16527401 0.83 MAOA (0.70) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL7332806 0.83 ESR1 (0.72) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL12781553 0.83 MAOA (0.70) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL7333754 0.83 MAOA (1.00) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL20317210 0.83 MAOA (0.70) MAOANPC1KDM4ERAB9AALDH1A1
SCHEMBL30786763 0.83 MAOA (0.70) MAOANPC1KDM4ERAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117420731-A Negative photosensitive composition and pattern forming method 东京应化工业株式会社 2024-01-19 CN disclosed
CN-116018558-A Negative photosensitive resin composition, pattern forming method and laminated film 三亚普罗股份有限公司 2023-04-25 CN disclosed
WO-2020162638-A1 COMPOSITION FOR AMELIORATING MALIGNANT TUMOR DISEASES 学校法人近畿大学 2020-08-13 WO disclosed
EP-3339395-B1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2019-10-02 EP disclosed
EP-3339395-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME Samsung Electronics Co., Ltd. (KR) 2018-06-27 EP disclosed
EP-2980182-B1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2018-05-23 EP disclosed
US-20160035986-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-02-04 US disclosed
EP-2980182-A1 Condensed cyclic compound and organic light-emitting device including the same Samsung Electronics Co., Ltd. (KR) 2016-02-03 EP disclosed
EP-2313889-B1 IMAGING ELEMENT AND METHOD USING DIFFERENTIAL LIGHT SCATTERING EASTMAN KODAK CO (US) 2012-12-12 EP disclosed
US-8119328-B2 Imaging element and method using differential light scattering EASTMAN KODAK COMPANY (US) 2012-02-21 US disclosed
EP-0888052-A4 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORP (US) 2002-05-22 EP disclosed
US-20020055644-A1 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins INTERLAB, INC. 2002-05-09 US disclosed
WO-2001041773-A1 XANTHONE ANALOGS FOR TREATING INFECTIOUS DISEASES AND COMPLEXATION OF HEME AND PORPHYRINS INTERLAB, INC. (US) 2001-06-14 WO disclosed
US-5981774-A PREPARING 3,5-DI(2,3-EPOXYPROPOXY)-1-HYDROXYXANTHONE BY REACTING 1,3,5-TRIMETHOXYXANTHONE WITH HYDROGEN IODIDE IN PHENOL WHEREBY 1,3,5-TRIHYDROXYXANTHONE IS OBTAINED, REACTING PRODUCT WITH EPICHLOROHYDRIN IN POTASSIUM HYDROXIDE NATIONAL SCIENCE COUNCIL (TW) 1999-11-09 US disclosed
US-5977077-A PARASITICIDES; ANTIPROTOZOA AGENT INTERLAB CORPORATION (US) 1999-11-02 US disclosed
EP-0888052-A1 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORPORATION (US) 1999-01-07 EP disclosed
US-5741813-A ADMINISTERING SUBSTITUTED XANTHONES NATIONAL SCIENCE COUNCIL (TW) 1998-04-21 US disclosed
WO-1997034482-A1 XANTHONE ANALOGS FOR THE TREATMENT OF INFECTIOUS DISEASES INTERLAB CORP. (US) 1997-09-25 WO disclosed
US-5495005-A ANTICOAGULANTS, CARDIOVASCULAR DISORDERS NATIONAL SCIENCE COUNCIL (TW) 1996-02-27 US disclosed
US-4539412-A ANTITUMOR AGENTS RENSSELAER POLYTECHNIC INSTITUTE (US) 1985-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160035986-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CCNT1, CCNA1 MAOA 2783/4885NPC1 2351/4885KDM4E 2785/4885
US-20020055644-A1 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins XPA, XDH, HMOX1 MAOA 680/4885NPC1 961/4885KDM4E 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.